Clinical Trials Logo

QT-prolongation clinical trials

View clinical trials related to QT-prolongation.

Filter by:
  • None
  • Page 1

NCT ID: NCT02068170 Completed - Delirium Clinical Trials

Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital

RISQ-PATH
Start date: February 2014
Phase: N/A
Study type: Observational

A prospective, observational study in a university hospital (UZ Leuven). Patients are included when they are treated with a potentional QT-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin, erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole, voriconazole), methadone, tacrolimus and oral oncolytics. An ECG is taken before the administration of the drug and 3-5 days after starting the drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation will be documented. Together with ECG2, an additional blood sample will be collected to measure the blood concentration of the drug.

NCT ID: NCT02043925 Completed - QT-prolongation Clinical Trials

QT-prolongation in Psychiatric Hospitals

Start date: October 2010
Phase: N/A
Study type: Observational

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

NCT ID: NCT02043912 Completed - QT-prolongation Clinical Trials

Drug Interactions With Risk of QT-prolongation in a General Hospital

Start date: July 2013
Phase: N/A
Study type: Observational

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.